After conducting a thorough search using DrugPatentWatch.com, I was unable to find specific information regarding the approval date for Apotex's ruxolitinib. However, I can provide some context around ruxolitinib and Apotex.

Ruxolitinib is a medication that is used to treat certain types of myelofibrosis, a bone marrow disorder, and polycythemia vera, a type of blood cancer. It works by blocking the action of certain enzymes in the body that are involved in the growth and development of cancer cells.

Apotex is a Canadian-based pharmaceutical company that produces a variety of generic and innovative medications. They have a wide range of products in various therapeutic areas, including oncology, cardiology, and respiratory diseases.

While I cannot provide the exact approval date for Apotex's ruxolitinib, it is important to note that the drug was first approved by the FDA in November 2011 under the brand name Jakafi, which is marketed by Incyte Corporation. Generic versions of ruxolitinib, including Apotex's, may become available after the patent for Jakafi expires.

Sources:

1. DrugPatentWatch.com. (n.d.). Ruxolitinib. Retrieved from <https://www.drugpatentwatch.com/drugs/ruxolitinib>
2. U.S. Food and Drug Administration. (2011, November 16). FDA approves new drug to treat certain types of myelofibrosis. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-certain-types-myelofibrosis>
3. Apotex. (n.d.). About us. Retrieved from <https://www.apotex.com/about-apotex>